<DOC>
	<DOCNO>NCT01998633</DOCNO>
	<brief_summary>HLH , HLH-related disorder , Chronic Granulomatous ( CGD ) , HIGM1 , Immune dysregulation , polyendocrinopathy , enteropathy , X-linked inheritance ( IPEX ) severe LAD-I represent primary immune disorder typically fatal without Hematopoietic Cell Transplant ( HCT ) . However , transplant often complicate inflammation , infection co-morbidities . In addition , disorder show cured partial chimerism , make ideal target use reduce intensity approach , portion patient may achieve full donor chimerism , instead achieve stable mixed chimerism . Reduced-intensity conditioning strategy demonstrate improved survival decrease Treatment Related Mortality ( TRM ) institutional series patient HLH ( Cooper et al. , 2006 ; Marsh et al. , 2010 ; Marsh et al. , 2011 ) . However , graft loss unstable chimerism remain challenge . An institutional case series Cincinnati Children 's Hospital demonstrate full high-level chimerism improve durable engraftment use intermediate ( Day -14 ) time alemtuzumab ( Marsh et al. , 2013b ) . This study aim test efficacy Intermediate RIC strategy prospective multi-center study include HLH well primary immunodeficiency allogeneic transplant RIC show feasible stable chimerism curative .</brief_summary>
	<brief_title>Reduced Intensity Conditioning Hemophagocytic Syndromes Selected Primary Immune Deficiencies ( BMT CTN 1204 )</brief_title>
	<detailed_description>The primary goal Phase II clinical trial determine one-year overall survival patient treat immune deficiency include HLH , HLH-like disorder , CGD , HIGM1 , IPEX syndrome , severe LAD-I Matched Related Donor ( MRD ) / Matched Unrelated Donor ( MUD ) bone marrow transplant use reduced-intensity conditioning strategy include intermediate-timing alemtuzumab . The donor choice unaffected related bone marrow donor 6/6 match HLA-A , -B ( intermediate high resolution ) -DRB1 ( high resolution use DNA-based typing ) OR 7/8 8/8 match human leukocyte antigen ( HLA ) -A , -B , -C -DRB1 ( high resolution use DNA-based typing ) , OR unrelated bone marrow donor 7/8 8/8 match HLA-A , -B , -C -DRB1 ( high resolution use DNA-based typing ) . The transplant conditioning regimen include fludarabine , melphalan , alemtuzumab start Day -14 ( Flu/Mel/Alem ) . Graft Versus Host Disease ( GVHD ) prophylaxis consist cyclosporine corticosteroid engraftment . Post-transplant supportive care include infection surveillance prophylaxis , disease-specific supportive care .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>Epstein-Barr Virus Infections</mesh_term>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<criteria>Inclusion Criteria 1 . Patient ≥ 3 month ≤ 45 year age time enrollment . 2 . Meets criteria one follow immune disorder ( 2A2F ) require HCT : 2A . HLH related disorder indication HCT [ . Inherited gene mutation associate HLH : PRF1 , UNC13D ( MUNC132 ) , STXBP2 ( MUNC182 ) , STX11 , RAB27A ( Griscelli syndrome , type 2 ) , SH2D1A ( XLP1 ) , XIAP ( XLP2 ) , LYST ( ChediakHigashi syndrome ) OR b . Meets clinical criterion HLH , refractory therapy accord HLH94 HLH2004 ( dexamethasone/etoposide ) , recurrent episode hyperinflammation OR c. Meets clinical criterion HLH , without identify gene defect , affect sibling OR decrease absent NK cell function last evaluation , OR history CNS inflammation evidence pleocytosis CSF MRI evidence hyperinflammation CNS ] 2B . CAEBV : Patients chronic EBV infection ( CAEBV ) without associate lymphoma ( complete remission ) active HLH . Note diagnosis distinct posttransplant lymphoproliferative disorder/ EBVassociated lymphoproliferative disease ( PTLD/LPD ) . [ Patients must meet following : . Severe progressive illness , usually fever , lymphadenopathy splenomegaly either begin primary EBV infection associate markedly elevate antibody titer EBV viral capsid antibody ( ≥ 1:5120 ) early antigen ( ≥ 1:640 ) , markedly elevate EBV DNA blood ; AND b. Infiltration tissue ( e.g. , lymph node , liver , lung , CNS , bone marrow , eye , skin ) lymphocytes ; AND c. Elevated EBV DNA , RNA proteins affected tissue ; AND d. The absence HIV posttransplant lymphoproliferative disorder ] 2C . Chronic granulomatous disease indication HCT [ a. Oxidative burst &lt; 10 % normal dihydrorhodamine ( DHR ) assay AND b. Documented CGD mutation ( ) gp91phox , p47phox , p67phox , p22phox p40phox AND c. Severe disease evidence one following : history one potentially lifethreatening infection ; inflammatory bowel disease ; failure thrive height &lt; 10 % age ( unless parent ( ) height &lt; 10 % ) ; autoimmune complication felt link CGD ] 2D . Xlinked Hyper IgM Syndrome ( HIGM1 ) [ . Decreased serum IgG ( 2 standard deviation normal age ) AND b. Mutation CD40LG OR family history maternally related male HIGM1 ] 2E . IPEX Syndrome [ . Absent FOXP3+ CD4+ T cell OR abnormal function FOXP3+CD4+ T cell AND b. Diseaseassociated mutation FoxP3 ( biallelic female ) OR family history maternally related male clinical diagnosis IPEX ] 2F . Severe Leukocyte Adhesion Deficiency , type I ( LADI ) [ . Decreased CD18 expression neutrophil ( &lt; 5 % normal age ) AND b. Mutation ITGB2 OR absence ITGB2 mRNA leukocytes ] 3 . Lansky Karnofsky performance status ≥ 50 % . 4 . The patient 's donor must willing able give bone marrow stem cell : . An unaffected sibling donor 6/6 match HLAA B ( intermediate high resolution ) DRB1 ( high resolution use DNAbased type ) OR b . An unaffected related donor ( sibling ) 7/8 8/8 match HLAA , B , C ( intermediate high resolution ) DRB1 ( high resolution use DNAbased type ) OR c. An unrelated donor 7/8 8/8 match HLAA , B , C , DRB1 ( high resolution use DNAbased type ) . 5 . Patient must adequate organ function measure : 1 . Cardiac : Left ventricular ejection fraction ( LVEF ) &gt; 40 % ; LV shorten fraction ( LVSF ) &gt; 26 % echocardiogram . 2 . Renal : Calculated radioisotope Glomerular Filtration Rate ( GFR ) &gt; 50 mL/min/1.73m^2 3 . Hepatic : Adequate liver function : serum conjugate ( direct ) bilirubin &lt; 2x upper limit normal age per local laboratory ( exception isolate hyperbilirubinemia due Gilbert 's syndrome , hyperbilirubinemia result liver inflammation set persistent , active HLH ) ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 10x upper limit normal per local laboratory ( exception elevate transaminase level result liver inflammation set persistent , active HLH ) . 4 . Pulmonary : Patient may mechanical ventilation support progressive pulmonary infection time transplant ; Pulmonary Function Testing ( PFT ) force expiratory volume one second ( FEV1 ) &gt; 50 % normal Diffusing capacity lung carbon monoxide ( DLCO ) correct Hgb &gt; 50 % normal . Patients unable undergo PFTs stable respiratory status SaO2 &gt; 90 % maximum 2L/min supplemental oxygen . 6 . Signed informed consent . 1 . Hematopoietic stem cell transplant within 6 month enrollment . 2 . Uncontrolled bacterial , viral fungal infection ( currently receive appropriate antimicrobial experience progression clinical improvement ) time enrollment . We recognize patient CAEBV may ongoing EBV viremia time initiate transplant therapy , patient uncontrolled bacterial , viral fungal infection time enrollment ( prior initiate preparative regimen ) . 3 . Pregnant breastfeeding . 4 . Seropositive human immunodeficiency virus ( HIV ) . 5 . Alemtuzumab within 2 week enrollment . 6 . History prior current malignancy , especially malignancy likelihood relapse progression , exception ( 1 ) EBVassociated lymphomas relate immune deficiency lymphoma associate Xlinked LPD good remission , unlikely relapse treatment ; ( 2 ) Resected basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent allow unless approve Protocol Officer one Protocol Chairs .</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hemophagocytic lymphohistiocytosis</keyword>
	<keyword>Chronic Active EBV</keyword>
	<keyword>Chronic Granulomatous Disease</keyword>
	<keyword>Hyperimmunoglobulin M Syndrome ( Hyper IGM )</keyword>
	<keyword>Leukocyte Adhesion Deficiency</keyword>
	<keyword>IPEX</keyword>
	<keyword>Hematopoietic Stem Cell Transplant ( HSCT )</keyword>
	<keyword>Non-Myeloablative Transplant ( NST )</keyword>
	<keyword>Reduced-Intensity Conditioning ( RIC )</keyword>
</DOC>